Tumors in Italy: an overview

Istituto Superiore di Sanità data’s say that the national average of patients who are screened for colorectal cancer is 42.6% (60% in the north, 20% in the south).

These data are not too surprising, considering that the diagnostic tools currently most used (fecal occult blood research and rectosigmoidoscopy / colonoscopy) are invasive and expensive tests, which discourage patients and have a significant margin of error.

Source: The European House – Ambrosetti, based on data produced by Istituto Superiore della Sanità, 2019.

During the year 2020, the incidence of malignant neoplasms is estimated to be 377,000 new cases.
In both sexes, the incidence increases with age and is higher in males. The graphs show the progressive incidence of neoplasms in the 3 age groups considered (0 49; 50-69;> 70 years).

The absolute numbers and percentages refer to incident tumors in each of the 3 age groups.
For each age group, the 3 most frequent neoplastic sites are indicated.

Year 2020: new cases of malignant neoplasms
accidents in the Italian male population

Year 2020: new cases of malignant neoplasms
accidents in the Italian female population.

In males, the general decrease in cancer mortality can be traced to the reduction in mortality rates of tobacco-related cancers, an effect that has not been seen in females, among which anti-smoking campaigns can help control the cancer epidemic. lung and other tobacco-related cancers.

Although particular merit in reducing mortality rates can be attributed to the refinement of diagnostic techniques and therapeutic advances, these positive effects have not been recorded for pancreatic cancer, for which significant progress is lacking in both diagnosis and treatment.

Mortality rates (per 100,000 population) from cancer observed
in Italy in 2015 and projections in 2020 by gender.

Mortality rates (per 100,000 population) from cancer observed
in Europe in 2015 and projections in 2020 by gender.

MISTRAL: THE PERFECT SOLUTION FOR EARLY DIAGNOSIS

Mistral is the innovative diagnostic technology that monitors metabolic alterations related to the onset of pathologies.
Breath Analysis and Mistral allow mass screening investigations because they are quick, simple and non-invasive.

Mistral is innovation that puts people at the center, to improve the work of doctors and the health of all of us.

This site uses cookies to improve the browsing experience of users and to gather information on the use of the site. You can know the details by consulting our cookie policy.